Snowden Capital Advisors’s Atossa Therapeutics ATOS Stock Holding History

Snowden Capital Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20	Closed	–	–	1099
2021 Q4	$0	Buy	+20	New	+$732	﹤0.01%	2038

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Snowden Capital Advisors's ATOS Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Atossa Therapeutics (ATOS) in Q1 2022, closing a stake of 20 shares.

Snowden Capital Advisors first reported a position in ATOS in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

Snowden Capital Advisors reported no remaining Atossa Therapeutics position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 20 Atossa Therapeutics shares in Q1 2022.
Snowden Capital Advisors first reported a position in Atossa Therapeutics in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Atossa Therapeutics position peaked at $0 in Q4 2021.
83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.